U.S. Crackdown on Chinese Biotech Could Harm Patientsby Lilu Anderson 22.06.2024America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patientsby Mark Eisenberg 22.06.2024Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
AbbVie Sets $1.55 Quarterly Dividend, Piper Sandler Ups Targetby Mark Eisenberg 22.06.2024AbbVie sets quarterly dividend at $1.55 per share, showcasing financial health and strategic growth. Recent acquisitions bolster positive outlook.
Zealand Pharma Surges on Promising Weight Loss Drug Trial Resultsby Mark Eisenberg 21.06.2024Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
European Stocks Dip: Tech, Banks Dragging STOXX 600 Downby Mark Eisenberg 21.06.2024European stocks dipped Friday as tech and banks struggled amidst Carlsberg's slump and weak economic data, despite UK retail sales ...
Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertainby Lilu Anderson 20.06.2024Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Esperion Stock Downgraded Amid Merck’s Competitive Pressureby Mark Eisenberg 20.06.2024Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
ADC Therapeutics Director Azelby Sells Shares Amid Price Target Cutby Mark Eisenberg 20.06.2024Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
Iontronic Tech Promises Hope in Slowing Malignant Brain Tumorsby Lilu Anderson 20.06.2024"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
Day One Biopharma Expands to ADCs with $55M Drug Acquisitionby Lilu Anderson 19.06.2024"Day One Biopharmaceuticals enhances pipeline, acquiring global rights to promising PTK7-targeting cancer drug DAY301, begins trial soon."